Tim Cortese

Investigators highlighted that emotional and cognitive consequences of beliefs were primarily negative among caregivers of children with cancer.

Data from the ROSELLA trial support the approval of relacorilant plus nab-paclitaxel in this ovarian cancer population.

The MyChoice CDx was approved based on its performance determining HRD status and stratifying patients in the phase 3 PRIMA trial.

In each decade since the launch of the journal ONCOLOGY, cancer care has evolved, and with it the finances and costs associated with these improving treatments.

The future of radiation oncology will be largely affected by artificial intelligence and genomics, according to Sheila D. Rege, MD, FACRO.

Marc Lehrer Greenwald, MD, spoke with CancerNetwork® about how North Shore University Hospital treats young patients with colorectal cancer.

Marwan G. Fakih, MD, discussed many of the factors he considers when deciding on a treatment for a patient with metastatic colorectal cancer.

Updated results from the phase 3 KEYNOTE-B96 trial revealed that pembrolizumab plus paclitaxel with or without bevacizumab improved OS in all comers.

Loretta Nastoupil, MD, reflected on some of the differences between practicing in a rural, community cancer center compared with a larger institutional center.

The FDA approved zongertinib in HER2-mutated NSCLC as part of its Commissioner's National Priority Voucher pilot program.

The guidelines offer best practices for diagnoses, classification, systemic treatment, radiation therapy, and surgery for patients with RMS.

The role of bispecific antibodies in mantle cell lymphoma treatment remains unclear, and they are not readily available in community sites, according to Tycel Phillips, MD.

Dominique Rash, MD, presented several cases of patients with inoperable endometrial cancer at the 2026 ACRO Summit.

Michael Buckstein, MD, spoke with CancerNetwork about the benefits of using radiation to treat celiac plexus-associated pain.

Theranostics, a technique that combines traditional medication with diagnostics, is “limitless,” according to Brandon Mancini, MD, MBA, FACRO.

According to investigators of the phase 3 SCOT trial, most patients with colon and rectal cancer should be receiving only 3 months of adjuvant treatment.

One of the lesser-known costs of undergoing cancer treatment is the loss of work opportunities, according to Loretta Nastoupil, MD.

People who consumed 14 or more drinks per week experienced a higher risk of colorectal cancer compared with those who consumed one or fewer drinks.

Anbenitamab plus chemotherapy reduced the risk of progression or death by 75% vs chemotherapy alone in select patients with gastric cancer/gastroesophageal adenocarcinoma.

With a median follow-up of 6 months, the median OS was not yet reached in patients with recurrent glioblastoma with the nogapendekin alfa inbakicept-based regimen.

Data from the phase 3 BREAKWATER trial demonstrated that encorafenib plus cetuximab and chemotherapy yields clinical benefit for this patient population.

Treatment with relacorilant plus nab-paclitaxel yielded a 35% reduction in the risk of death compared with nab-paclitaxel alone for patients with platinum-resistant ovarian cancer.

Bezuclastinib plus sunitinib yielded favorable PFS and ORR data vs sunitinib alone in patients with previously treated gastrointestinal stromal tumors.

Data from 2 trials at the 2024 and 2025 ASCO Annual Meetings demonstrate the PD-L1/4-1BB bispecific antibody’s efficacy and safety in this population.

The folate receptor α ADC yielded responses, with a favorable safety profile, in patients with high-grade serous ovarian cancer in a phase 1 trial.

Patients with pancreatic cancer who received up to 6 infusions of the multiantigen-targeted T cell product only experienced 1 treatment-related serious AE.

Patients with HER2-mutant NSCLC who were naïve to systemic therapy for advanced disease experienced positive results following treatment with sevabertinib.

Results from the phase 3 VERIFY and phase 2 REVIVE studies supported the NDA submission of the for rusfertide in this PV patient population.

The majority of patients with de novo DLBCL who received zanubrutinib plus rituximab and lenalidomide achieved complete responses in a phase 2 trial.

Olvimulogene nanivacirepvec yielded 3 partial responses among 9 evaluable patients with SCLC who had progression or recurrence on prior therapy.